SAN FRANCISCO, Aug. 4, 2015 – Sutro Biopharma today announced that it has appointed Nicki Vasquez, Ph.D., as vice president of alliance and project management. Dr. Vasquez will have a leadership role in the management of Sutro’s collaborative partnerships and the development of Sutro’s cancer therapeutics pipeline, including antibody-drug conjugates, bispecific antibodies and antibody-based therapeutics targeting immuno-oncology pathways.
Dr. Vasquez brings more than 22 years of experience in the biopharmaceutical sector with expertise in management of preclinical and clinical therapeutic development; as well as expertise in research operations and program management. Most recently, she was vice president of program and portfolio management at StemCells, Inc.; where she was responsible for building and driving forward R&D program management for the company’s preclinical and lead phase 2 programs.
Prior to StemCells, Dr. Vasquez held several senior positions at Elan (now acquired by Perrigo) including the following: vice president, global development program & portfolio management, and vice president, research operations & program management. While at Elan, she helped to manage therapeutic candidate programs in all stages of research and early clinical development, and held senior alliance management roles for the company’s Tysabri® collaboration with Biogen. Dr. Vasquez received her Ph.D. in Immunology at the University of California in San Diego and postdoctoral training at Genentech.
About Sutro Biopharma
Sutro Biopharma, Inc., located in South San Francisco, develops best-in-class antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy, including Immuno-Oncology therapies. Sutro’s discovery and development efforts are driven by our proprietary Xpress CF- and Xpress CF+-platforms, a biochemical synthesis system that enables rapid and systematic evaluation of protein structure-activity relationships, as well as rapid and predictable scalability for manufacturing in Sutro’s cGMP facility. In addition to developing its own drug candidate pipeline, which is focused on mono- and bi-specific ADCs Sutro Biopharma is collaborating with select pharmaceutical and biotech companies to discover and develop novel therapeutics.